OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kim on the FDA Approval of TheraSphere Y-90 Glass Microspheres in HCC

April 30th 2021

Edward Kim, MD, discusses the FDA approval of TheraSphere™ Yttrium-90 Glass Microspheres in hepatocellular carcinoma.

Dr. Hahn on the Convenience of Subcutaneous Trastuzumab/Pertuzumab in HER2+ Breast Cancer

April 30th 2021

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Dr. Saltos on the Importance of Broad Molecular Testing in NSCLC

April 30th 2021

Andreas Saltos, MD, discusses the importance of broad molecular testing in non–small cell lung cancer.

Dr. Radich on the Impact of MRD on Survival Outcomes in AML

April 30th 2021

Jerald Radich, MD, discusses the impact of minimal residual disease on survival outcomes in patients with acute myeloid leukemia.

Dr. Fleury on the Advancement of Decentralized Clinical Trials During COVID-19

April 29th 2021

Mark Fleury, PhD, discusses the advancement of decentralized clinical trials during the COVID-19 pandemic.

Dr. Williams on Selecting Between CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

April 29th 2021

Nicole O. Williams, MD, discusses treatment considerations for selecting between CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Dr. Monk on the Clinical Implications of the PRIMA Trial in Advanced Ovarian Cancer

April 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the clinical implications of the phase 3 PRIMA trial in newly diagnosed advanced ovarian cancer.

Dr. Cohen on Future Research Directions in Head and Neck Cancer

April 29th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Dr. Moreau on the FDA Approval of Isatuximab Plus Carfilzomib/Dexamethasone in Multiple Myeloma

April 28th 2021

Philippe Moreau, MD, discusses the FDA approval of isatuximab-irfc plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Dr. Kazandjian on Evaluating Retreatment With BCMA-Directed Therapy in Multiple Myeloma

April 28th 2021

Dickran G. Kazandjian, MD, discusses the rationale to evaluate retreatment with BCMA-directed therapy in multiple myeloma.

Dr. Costa on Developing Later-Line Therapies for the Frontline Setting in Multiple Myeloma

April 28th 2021

Luciano J. Costa, MD, PhD, discusses the rationale to develop later-line therapies for use in the frontline setting in multiple myeloma.

Dr. Shah on the Efficacy and Safety of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

April 28th 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Dr. Devitt on Utilizing PD-L1 in Biomarker-Guided Therapies in Bladder Cancer

April 28th 2021

Michael Devitt, MD, discusses utilizing PD-L1 status in biomarker-guided therapies for patients with bladder cancer.

Dr. Grunwald on the Efficacy of 19-28z CAR T-Cell Therapy in B-ALL

April 27th 2021

Michael R. Grunwald, MD, FACP, discusses the efficacy of 19-28z CAR T-cell therapy in B-cell acute lymphoblastic leukemia.

Dr. Rapisuwon on Frontline Immunotherapy Vs Targeted Therapy in Melanoma Subtypes

April 27th 2021

Suthee Rapisuwon, MD, discusses the utility of frontline immunotherapy vs targeted therapy in acral and mucosal melanoma.

Dr. Miller on the Potential Utility of Sequential PARP Inhibition in Ovarian Cancer

April 27th 2021

Eirwen M. Miller, MD, discusses the potential utility of sequential PARP inhibition in ovarian cancer.

Dr. Mohindra on the Impact of Lurbinectedin in SCLC

April 27th 2021

Nisha A. Mohindra, MD, discusses the impact of the FDA approval of lurbinectedin in the treatment of patients with small cell lung cancer.

Dr. Rini on the Mechanism of Action of Tivozanib in Relapsed/Refractory RCC

April 26th 2021

Brian I. Rini, MD, discusses the mechanism of action of tivozanib in relapsed/refractory renal cell carcinoma.

Dr. Usmani on the Potential Future of Isatuximab in Multiple Myeloma

April 26th 2021

Saad Z. Usmani, MD, FACP, discusses the potential future utility of isatuximab-irfc in multiple myeloma.

Dr. Raz on the Effects of COVID-19 on Lung Cancer Screening

April 26th 2021

Dan J. Raz, MAS, MD, discusses the effects of COVID-19 on lung cancer screening.